Connor, Clark & Lunn Investment Management Ltd. Corvus Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 137,031 shares of CRVS stock, worth $930,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares

137,031

Previous 83,222 64.66%

Holding current value

$930,440

Previous $151,000 378.81%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$1.78 - $5.92 $95,780 - $318,549	53,809 Added 64.66%	137,031 $723,000
Q2 2024 Aug 09, 2024	SELL	$1.36 - $2.29 $6,508 - $10,959	-4,786 Reduced 5.44%	83,222 $151,000
Q1 2024 May 09, 2024	BUY	$1.76 - $2.41 $29,568 - $40,488	16,800 Added 23.59%	88,008 $156,000
Q4 2023 Feb 09, 2024	BUY	$1.08 - $1.92 $351 - $624	325 Added 0.46%	71,208 $125,000
Q3 2023 Nov 13, 2023	SELL	$1.41 - $2.97 $19,013 - $40,050	-13,485 Reduced 15.98%	70,883 $103,000
Q2 2023 Aug 10, 2023	BUY	$1.0 - $3.86 $84,368 - $325,660	84,368 New	84,368 $193,000
Q3 2020 Nov 12, 2020	SELL	$2.6 - $5.37 $220,786 - $456,009	-84,918 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$2.01 - $4.05 $1,378 - $2,778	-686 Reduced 0.8%	84,918 $231,000
Q1 2020 May 13, 2020	BUY	$1.74 - $5.98 $6,618 - $22,747	3,804 Added 4.65%	85,604 $180,000
Q4 2019 Feb 12, 2020	BUY	$2.56 - $5.44 $18,112 - $38,488	7,075 Added 9.47%	81,800 $445,000
Q3 2019 Nov 13, 2019	BUY	$3.01 - $6.5 $31,303 - $67,600	10,400 Added 16.17%	74,725 $225,000
Q2 2019 Aug 07, 2019	BUY	$3.3 - $4.58 $17,734 - $24,612	5,374 Added 9.12%	64,325 $241,000
Q1 2019 May 08, 2019	BUY	$3.75 - $4.97 $34,128 - $45,231	9,101 Added 18.26%	58,951 $237,000
Q4 2018 Feb 12, 2019	BUY	$3.29 - $8.94 $5,264 - $14,304	1,600 Added 3.32%	49,850 $183,000
Q3 2018 Nov 13, 2018	BUY	$8.58 - $11.4 $5,577 - $7,410	650 Added 1.37%	48,250 $414,000
Q2 2018 Aug 02, 2018	BUY	$9.42 - $13.73 $27,318 - $39,817	2,900 Added 6.49%	47,600 $523,000
Q1 2018 May 14, 2018	BUY	$7.48 - $11.53 $96,492 - $148,737	12,900 Added 40.57%	44,700 $515,000
Q4 2017 Feb 09, 2018	BUY	$9.3 - $16.93 $43,710 - $79,571	4,700 Added 17.34%	31,800 $329,000
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $53,110 - $80,981	4,700 Added 20.98%	27,100 $432,000
Q2 2017 Aug 14, 2017	BUY	N/A	22,400	22,400 $271,000

Others Institutions Holding CRVS

# of Institutions

Shares Held

30.4M

Call Options Held

1.06M

Put Options Held

84.3K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $316M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Corvus Pharmaceuticals, Inc. Transaction History